GeoVax Labs (GOVX) 10-Q 11 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Document Information [Line Items]
Entity Central Index Key	0000832489
Entity Registrant Name	GeoVax Labs, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-39563
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0455038
Entity Address, Address Line One	1900 Lake Park Drive, Suite 380
Entity Address, City or Town	Smyrna
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30080
City Area Code	678
Local Phone Number	384-7220
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,327,702
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to Purchase Common Stock
Trading Symbol	GOVXW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock $0.001 par value
Trading Symbol	GOVX
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 19,538,513	$ 9,883,796
Grant funds and other receivables	0	182,663
Prepaid expenses and other current assets	118,038	168,689
Total current assets	19,656,551	10,235,148
Property and equipment, net	149,799	147,741
Deposits	11,010	11,010
Total assets	19,817,360	10,393,899
Current liabilities:
Accounts payable	289,680	267,702
Accrued expenses	69,342	359,281
Current portion of notes payable	0	183,326
Total current liabilities	359,022	810,309
Note payable, net of current portion	0	14,738
Total liabilities	359,022	825,047
Commitments (Note 8)
Stockholders’ equity:
Preferred Stock, $.01 par value: Authorized shares – 10,000,000: Series B convertible preferred stock, $1,000 stated value; Authorized shares – 10,000,000; 100 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	0	76,095
Common stock, $.001 par value; Authorized shares – 600,000,000; Issued and outstanding shares – 6,315,467 and 3,834,095 at March 31, 2021 and December 31, 2020, respectively	6,328	3,834
Additional paid-in capital	68,134,402	55,294,504
Accumulated deficit	(48,682,392)	(45,805,581)
Total stockholders’ equity	19,458,338	9,568,852
Total liabilities and stockholders’ equity	$ 19,817,360	$ 10,393,899

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, stated value (in dollars per share)	0.01	0.01
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	600,000,000	600,000,000
Common stock, issued (in shares)	6,327,702	3,834,095
Common stock, outstanding (in shares)	6,327,702	3,834,095
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, stated value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	100
Preferred stock, shares outstanding (in shares)	0	100

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Grant and collaboration revenue	$ 79,708	$ 440,602	$ 190,125	$ 1,156,579
Operating expenses:
Research and development	832,835	461,421	1,435,618	1,270,357
General and administrative	733,499	427,292	1,805,209	929,637
Total operating expenses	1,566,334	888,713	3,240,827	2,199,994
Loss from operations	(1,486,626)	(448,111)	(3,050,702)	(1,043,415)
Other income (expense):
Interest income	1,068	60	3,121	812
Interest expense	(531)	(7,153)	(1,286)	(8,295)
Gain on debt extinguishment	172,056	0	172,056	0
Total other income (expense)	172,593	(7,093)	173,891	(7,483)
Net loss	$ (1,314,033)	$ (455,204)	$ (2,876,811)	$ (1,050,898)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.21)	$ (0.66)	$ (0.49)	$ (2.27)
Weighted average shares outstanding (in shares)	6,322,799	691,155	5,830,165	462,775

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	2,486	14,992
Balance at Dec. 31, 2019	$ 1,932,433	$ 15	$ 39,340,509	$ (42,847,513)	$ (1,574,556)
Issuance of common stock for services (in shares)		521
Issuance of common stock for services		$ 1	5,999		6,000
Net loss				(595,694)	(595,694)
Balance (in shares) at Mar. 31, 2020	400	689,581
Balance at Mar. 31, 2020	$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	300
Sale of convertible preferred stock for cash and cancellation of note payable	$ 300,000				300,000
Conversion of preferred stock to common stock (in shares)	(2,386)	674,068
Conversion of preferred stock to common stock	$ (1,856,338)	$ 674	1,855,664
Balance (in shares) at Dec. 31, 2019	2,486	14,992
Balance at Dec. 31, 2019	$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Net loss					(1,050,898)
Balance (in shares) at Jun. 30, 2020	400	691,705
Balance at Jun. 30, 2020	$ 376,095	$ 692	41,672,003	(43,898,411)	(1,849,621)
Balance (in shares) at Mar. 31, 2020	400	689,581
Balance at Mar. 31, 2020	$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Issuance of common stock for services (in shares)	0	2,124
Issuance of common stock for services	$ 0	$ 2	11,998	0	12,000
Net loss	$ 0	$ 0	0	(455,204)	(455,204)
Balance (in shares) at Jun. 30, 2020	400	691,705
Balance at Jun. 30, 2020	$ 376,095	$ 692	41,672,003	(43,898,411)	(1,849,621)
Warrants issued in bridge financing	$ 0	$ 0	457,833	0	457,833
Balance (in shares) at Dec. 31, 2020	100	3,834,095
Balance at Dec. 31, 2020	$ 76,095	$ 3,834	55,294,504	(45,805,581)	9,568,852
Sale of common stock for cash (in shares)	0	1,644,000
Sale of common stock for cash	$ 0	$ 1,644	9,407,276	0	9,408,920
Common stock issued (in shares)	0	835,900
Issuance of common stock upon warrant exercise	$ 0	$ 836	3,173,320	0	3,174,156
Issuance of common stock for services (in shares)	0	1,472
Issuance of common stock for services	$ 0	$ 1	5,999	0	6,000
Stock option expense			56,190		56,190
Net loss				(1,562,778)	(1,562,778)
Balance (in shares) at Mar. 31, 2021	100	6,315,467
Balance at Mar. 31, 2021	$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Balance (in shares) at Dec. 31, 2020	100	3,834,095
Balance at Dec. 31, 2020	$ 76,095	$ 3,834	55,294,504	(45,805,581)	$ 9,568,852
Issuance of common stock for services (in shares)					13,707
Net loss					$ (2,876,811)
Balance (in shares) at Jun. 30, 2021	0	6,327,702
Balance at Jun. 30, 2021	$ 0	$ 6,328	68,134,402	(48,682,392)	19,458,338
Balance (in shares) at Mar. 31, 2021	100	6,315,467
Balance at Mar. 31, 2021	$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Issuance of common stock for services (in shares)	0	12,235
Issuance of common stock for services	$ 0	$ 13	65,828	0	65,841
Stock option expense	0	0	56,190	0	56,190
Net loss	$ 0	$ 0	0	(1,314,033)	(1,314,033)
Repurchase of preferred stock (in shares)	(100)	0
Repurchase of preferred stock	$ (76,095)	$ 0	75,095	0	(1,000)
Balance (in shares) at Jun. 30, 2021	0	6,327,702
Balance at Jun. 30, 2021	$ 0	$ 6,328	$ 68,134,402	$ (48,682,392)	$ 19,458,338

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (2,876,811)	$ (1,050,898)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	17,871	7,033
Stock-based compensation expense	198,821	18,000
Gain on debt extinguishment	(172,056)	0
Changes in assets and liabilities:
Grant funds and other receivables	182,663	(118,560)
Prepaid expenses and other current assets	36,051	54,850
Accounts payable and accrued expenses	(266,105)	164,082
Total adjustments	(2,755)	125,405
Net cash used in operating activities	(2,879,566)	(925,493)
Cash flows from investing activities
Purchase of equipment	(19,929)	0
Net cash used in investing activities	(19,929)	0
Cash flows from financing activities:
Net proceeds from sale of common stock	9,408,920	0
Net proceeds from sale of preferred stock	0	300,000
Net proceeds from warrant exercises	3,174,156	0
Net proceeds from bridge financing	0	888,500
Net proceeds from issuance of note payable	0	170,200
Repurchase of preferred stock	(1,000)	0
Principal repayment of note payable	(27,864)	(5,866)
Net cash provided by financing activities	12,554,212	1,352,834
Net increase in cash and cash equivalents	9,654,717	427,341
Cash and cash equivalents at beginning of period	9,883,796	283,341
Cash and cash equivalents at end of period	$ 19,538,513	$ 710,682

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Paycheck Protection Program CARES Act [Member]
Extinguishment of debt	$ 172,056
Conversion of Series H Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)		1,686
Conversion of stock, shares issued (in shares)		469,697
Conversion of Series I Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)		700
Conversion of stock, shares issued (in shares)		204,371
Stock Purchase Warrants First Issuance [Member]
Common stock issued (in shares)	145,866
Stock purchase warrants exercised (in shares)	188,668

Note 1 - Description of Busines

Note 1 - Description of Business	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or “GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation The accompanying condensed consolidated financial statements at June 30, 2021 three six June 30, 2021 2020 not 10 December 31, 2020. not We enacted reverse stock splits of our common stock on September 25, 2020 ( 1 January 21, 2020 ( 1 Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for at least the twelve We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We may may no

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 10 December 31, 2020 six June 30, 2021, no 10 no

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 583,336 and 503,785 shares for the three six June 30, 2021, three six June 30, 2020,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2021 December 31, 2020: June 30, 2021 December 31, 2020 Laboratory equipment $ 543,912 $ 532,100 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 19,853 11,736 Total property and equipment 679,370 659,441 Accumulated depreciation and amortization (529,571 ) (511,700 ) Property and equipment, net $ 149,799 $ 147,741

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of June 30, 2021 December 31, 2020: June 30, 2021 December 31, 2020 Accrued salaries and directors’ fees $ - $ 279,696 Other accrued expenses 69,342 79,585 Total accrued expenses $ 69,342 $ 359,281

Note 7 - Notes Payable

Note 7 - Notes Payable	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Notes Payable GRA Note February 28, 2018, five five three six June 30, 2021 2020. May 2021, CARES Act Paycheck Protection Program Loan April 17, 2020, one three six June 30, 2021, 2020. May 2021,

Note 8 - Commitments

Note 8 - Commitments	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. Commitments Lease Agreement We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2022. three six June 30, 2021 2020. 2021 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of June 30, 2021, 2021.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Preferred Stock [Text Block]	9. Stockholders Equity Preferred Stock June 7, 2021, June 30, 2021, Public Offering February 11, 2021, three Stock Options “2020 may 2020 six June 30, 2021, no 2020 June 30, 2021, Stock Purchase Warrants January February 2021, June 30, 2021, Other Common Stock Transactions six June 30, 2021, 10

Note 10 - Stock-Based Compensat

Note 10 - Stock-Based Compensation Expense	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. Stock-Based Compensation Expense Stock-based compensation expense related to employee and director stock options was $56,190 and $112,380 during the three six June 30, 2021, 2020. June 30, 2021, During the three six June 30, 2021, 2020. June 30, 2021,

Note 11 - Income Taxes

Note 11 - Income Taxes	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes Because of our historically significant net operating losses, we have not 382 may

Note 12 - Grants and Collaborat

Note 12 - Grants and Collaboration Revenue	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three six June 30, 2021, 2020. three six June 30, 2020, third June 30, 2021, 2021.

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2021 December 31, 2020 Laboratory equipment $ 543,912 $ 532,100 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 19,853 11,736 Total property and equipment 679,370 659,441 Accumulated depreciation and amortization (529,571 ) (511,700 ) Property and equipment, net $ 149,799 $ 147,741

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2021 December 31, 2020 Accrued salaries and directors’ fees $ - $ 279,696 Other accrued expenses 69,342 79,585 Total accrued expenses $ 69,342 $ 359,281

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Sep. 25, 2020	Jan. 21, 2020
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20	2,000

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	583,336	67,009	503,785	55,191

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Property and equipment, gross	$ 679,370	$ 659,441
Accumulated depreciation and amortization	(529,571)	(511,700)
Property and equipment, net	149,799	147,741
Laboratory Equipment [Member]
Property and equipment, gross	543,912	532,100
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 19,853	$ 11,736

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accrued salaries and directors’ fees	$ 0	$ 279,696
Other accrued expenses	69,342	79,585
Total accrued expenses	$ 69,342	$ 359,281

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Apr. 17, 2020	Feb. 28, 2018	May 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Proceeds from Notes Payable, Total						$ 0	$ 170,200
Repayments of Notes Payable						27,864	5,866
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 170,200
Interest Expense, Debt, Total				$ 233	$ 345	653	345
Extinguishment of Debt, Amount			$ 170,200
Gain (Loss) from Interest Forgiven			1,856
Senior Notes [Member]
Debt Instrument, Term (Year)		5 years
Proceeds from Notes Payable, Total		$ 50,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Interest Expense, Debt, Total				$ 297	$ 448	$ 633	$ 933
Repayments of Notes Payable			$ 22,737

Note 8 - Commitments (Details T

Note 8 - Commitments (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)ft²	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)ft²	Jun. 30, 2020USD ($)
Unrecorded Unconditional Purchase Obligation, Total	$ 1,047,000		$ 1,047,000
Unrecorded Unconditional Purchase Obligation Reimbursable, Amount	$ 211,326		$ 211,326
Office and Laboratory Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | ft²	8,400		8,400
Operating Lease, Expense	$ 42,803	$ 41,539	$ 85,607	$ 83,078
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	85,607		85,607
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 176,356		$ 176,356

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	Jun. 07, 2021	Feb. 11, 2021	Feb. 28, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Stock Repurchased During Period, Value				$ 1,000
Stock Issued During Period, Shares, New Issues (in shares)		1,644,000
Shares Issued, Price Per Share (in dollars per share)		$ 6.25
Proceeds from Issuance of Common Stock		$ 9,400,000			$ 9,408,920	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)				602,000	602,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)				$ 2.79	$ 2.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)					9 years 4 months 24 days
Proceeds from Warrant Exercises			$ 3,174,156		$ 3,174,156	$ 0
Stock Issued During Period, Shares, Issued for Services (in shares)					13,707
Stock Incentive Plan 2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				1,500,000	1,500,000
Representative Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		72,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.875
Class of Warrant or Right, Period for Warrants or Rights Exercisable (Day)		180 days
Warrants and Rights Outstanding, Term (Year)		3 years
Stock Purchase Warrants First Issuance [Member]
Class of Warrant or Right, Exercised During Period (in shares)			188,688		188,668
Stock Issued During Period, Shares, Warrants Exercised (in shares)			145,866		145,866
Stock Purchase Warrants Second Issuance [Member]
Class of Warrant or Right, Exercised During Period (in shares)			690,034
Stock Issued During Period, Shares, Warrants Exercised (in shares)			690,034
Stock Purchase Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 5.07	$ 5.07
Warrants and Rights Outstanding, Term (Year)				4 years 1 month 6 days	4 years 1 month 6 days
Class of Warrant or Right, Outstanding (in shares)				2,793,635	2,793,635
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)		204,000
Series B Convertible Preferred Stock [Member]
Stock Repurchased During Period, Shares (in shares)	100
Stock Repurchased During Period, Value	$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0	0		100

Note 10 - Stock-Based Compens_2

Note 10 - Stock-Based Compensation Expense (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 543,130		$ 543,130
Stock Issued During Period, Value Expensed During the Period, Issued for Services	30,573	$ 12,000	51,173	$ 18,000
Prepaid Expense, Value of Stock Issued for Services During Period	69,333		69,333
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense	$ 56,190	$ 0	$ 112,380	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 4 months 24 days

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Income Taxes Paid	$ 0

Note 12 - Grants and Collabor_2

Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer, Including Assessed Tax	$ 79,708	$ 440,602	$ 190,125	$ 1,156,579
Unused Grant Funds		275,302		275,302
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 79,708	301,493	$ 190,125	955,514
Leidos, Inc. Research Collaborative Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 139,109		$ 201,065